Now, the technology is making headlines again in cancer treatment. For the first time, a personalised mRNA cancer vaccine has ...

Baillie Gifford & Co, an independent investment management firm, released its third-quarter 2026 investor letter for “US Equity Growth Strategy”. The letter can be downloaded here. While AI safety and ...

Humana (HUM) and Lumentum Holdings (LITE) hit fresh 52-week highs on Friday as investors reacted to a planned NIH-backed cancer vaccine initiative, Humana’s Medicare Advantage ratings recovery and ...

New trial data in melanoma and early findings in head and neck cancer are advancing individualized vaccines, while questions remain about durability, biomarkers, and delivery.

Investors Should Know: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma ...

Moderna, Inc. was added back to the Nasdaq-100 index and earlier announced that former manufacturing leader Juan Andres would ...

New details have emerged about an initiative that starts in December to fast-track the vaccines, similar to the successful ...

Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.

Add Yahoo as a preferred source to see more of our stories on Google. With a little help, your immune cells can be potent tumor killers. Steve Gschmeissner/Science Photo Library via Getty Images The ...

The treatment can reprogram immune cells that have been corrupted by the cancer, strengthening the body’s ability to attack.

National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times ...

Covid-era conspiracy theories have continued to circulate in Indonesia, with a recent one falsely claiming messenger RNA ...